Muphoran (Fotemustine)

Fotemustine belongs to the nitrosourea class of alkylating agents. It generates reactive intermediates that covalently bind to DNA, forming cross‑links that block replication and transcription. This DNA damage triggers cell‑cycle arrest and apoptosis, preferentially targeting rapidly dividing tumor cells.

The dosing regimen for Muphoran is individualized by the treating physician based on the patient’s clinical status, tumor type, and organ function. Prescribers determine the appropriate dose, infusion rate, and treatment schedule according to established oncology protocols.

Fotemustine is classified as contraindicated in pregnancy because it can cross the placenta and cause fetal harm. Breastfeeding is also discouraged, as the drug may be excreted in milk and affect the infant. Women of child‑bearing potential should use effective contraception during treatment.

To request Muphoran, visit the product page on gnhindia.com, enter the required quantity, and submit the enquiry form. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

The primary alternative to fotemustine is temozolomide, an oral alkylating agent. Fotemustine is administered intravenously and may achieve higher central nervous system penetration, making it useful for certain brain tumors. Temozolomide offers oral convenience but has a different toxicity profile, with less severe myelosuppression but more gastrointestinal side effects.

Muphoran must be stored refrigerated at 2‑8 °C, protected from light, and never frozen. The product should remain in its original packaging until preparation. During handling, use aseptic technique and avoid exposure to heat or direct sunlight to maintain stability.

Muphoran is given as an intravenous infusion under medical supervision. The infusion is typically administered over a defined period, often 30‑60 minutes, depending on the prescribed protocol. Patients are monitored for infusion‑related reactions and vital signs throughout the procedure.

The most serious risks include severe myelosuppression leading to infection or bleeding, pulmonary fibrosis, hepatic toxicity that can progress to liver failure, and rare anaphylactic reactions. Prompt recognition of symptoms such as fever, shortness of breath, jaundice, or rash is essential for timely intervention.

Muphoran is contraindicated in patients with known hypersensitivity to fotemustine or other nitrosoureas, those with severe bone‑marrow suppression, uncontrolled infections, or significant hepatic or renal impairment. It should also be avoided in pregnant women unless the potential benefit justifies the risk.